{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:09:41Z","timestamp":1790687381480,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin de l'Acad\u00e9mie Nationale de M\u00e9decine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.banm.2022.02.005","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:11:55Z","timestamp":1645096315000},"page":"554-558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Les traitements par ARN interf\u00e9rents et par oligonucl\u00e9otides antisens actuellement disponibles\u00a0en France\u00a0: une mise au point"],"prefix":"10.1016","volume":"206","author":[{"given":"G.","family":"Bouvenot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.banm.2022.02.005_bib0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an ARNi therapeutic for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.banm.2022.02.005_bib0070","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Avis de la Commission de la transparence de la Haute Autorit\u00e9 de sant\u00e9. [En ligne] Disponible sur: www.has.sante.fr (acc\u00e9d\u00e9 le 16\/02\/2022)."},{"issue":"11","key":"10.1016\/j.banm.2022.02.005_bib0075","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"NEJM"},{"issue":"34","key":"10.1016\/j.banm.2022.02.005_bib0080","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3\u00a0trial of RNAi therapeutic Givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"NEJM"},{"issue":"13","key":"10.1016\/j.banm.2022.02.005_bib0085","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfels","year":"2021","journal-title":"NEJM"},{"issue":"16","key":"10.1016\/j.banm.2022.02.005_bib0090","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3\u00a0trials of Inclisiran in patients with elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"NEJM"},{"issue":"18","key":"10.1016\/j.banm.2022.02.005_bib0095","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"ENDEAR Study Group Nusinersen versus sham control in infantile-onset SMA","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.banm.2022.02.005_bib0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"CHERISH Study Group. Nusinersen versus sham control in later-onset SMA","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.banm.2022.02.005_bib0105","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of SMA; interim efficacy and safety results from the phase 2\u00a0Nurture study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromusc Disord"},{"issue":"1","key":"10.1016\/j.banm.2022.02.005_bib0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"NEJM"},{"issue":"6","key":"10.1016\/j.banm.2022.02.005_bib0115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrom","volume":"381","author":"Witzum","year":"2019","journal-title":"NEJM"},{"key":"10.1016\/j.banm.2022.02.005_bib0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas 9\u00a0in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"NEJM"}],"container-title":["Bulletin de l'Acad\u00e9mie Nationale de M\u00e9decine"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001407922000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001407922000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T23:02:17Z","timestamp":1757545337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001407922000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0001407922000668"],"URL":"https:\/\/doi.org\/10.1016\/j.banm.2022.02.005","relation":{},"ISSN":["0001-4079"],"issn-type":[{"value":"0001-4079","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les traitements par ARN interf\u00e9rents et par oligonucl\u00e9otides antisens actuellement disponibles\u00a0en France\u00a0: une mise au point","name":"articletitle","label":"Article Title"},{"value":"Bulletin de l'Acad\u00e9mie Nationale de M\u00e9decine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.banm.2022.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 l'Acad\u00e9mie nationale de m\u00e9decine. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}